813.53
price down icon0.80%   -6.57
after-market After Hours: 808.80 -4.73 -0.58%
loading
Lilly Eli Co stock is traded at $813.53, with a volume of 3.54M. It is down -0.80% in the last 24 hours and up +11.98% over the past month. Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio for cancer; Mounjaro, Zepbound, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.
See More
Previous Close:
$820.10
Open:
$827.31
24h Volume:
3.54M
Relative Volume:
0.79
Market Cap:
$769.97B
Revenue:
$53.26B
Net Income/Loss:
$13.80B
P/E Ratio:
53.94
EPS:
15.0808
Net Cash Flow:
$-50.20M
1W Performance:
+0.14%
1M Performance:
+11.98%
6M Performance:
-8.10%
1Y Performance:
-9.97%
1-Day Range:
Value
$809.63
$830.29
1-Week Range:
Value
$806.02
$834.15
52-Week Range:
Value
$623.78
$935.62

Lilly Eli Co Stock (LLY) Company Profile

Name
Name
Lilly Eli Co
Name
Phone
(317) 276-2000
Name
Address
LILLY CORPORATE CTR, INDIANAPOLIS, IN
Name
Employee
47,000
Name
Twitter
@LillyPad
Name
Next Earnings Date
2024-10-30
Name
Latest SEC Filings
Name
LLY's Discussions on Twitter

Compare LLY with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Drug Manufacturers - General icon
LLY
Lilly Eli Co
813.53 735.18B 53.26B 13.80B -50.20M 15.08
Drug Manufacturers - General icon
JNJ
Johnson Johnson
186.60 450.37B 92.15B 25.12B 20.46B 10.36
Drug Manufacturers - General icon
ABBV
Abbvie Inc
225.14 401.96B 58.33B 3.73B 18.24B 2.1013
Drug Manufacturers - General icon
NVS
Novartis Ag Adr
121.80 238.94B 53.40B 13.68B 16.89B 6.8864
Drug Manufacturers - General icon
MRK
Merck Co Inc
86.58 217.38B 63.43B 16.42B 14.72B 6.4861

Lilly Eli Co Stock (LLY) Upgrades & Downgrades

Date Action Analyst Rating Change
Oct-20-25 Reiterated BMO Capital Markets Outperform
Oct-14-25 Upgrade Erste Group Hold → Buy
Sep-17-25 Downgrade Berenberg Buy → Hold
Aug-27-25 Upgrade HSBC Securities Reduce → Hold
Aug-18-25 Downgrade Daiwa Securities Outperform → Neutral
Aug-07-25 Downgrade Leerink Partners Outperform → Market Perform
Jun-05-25 Downgrade Erste Group Buy → Hold
Apr-28-25 Downgrade HSBC Securities Buy → Reduce
Apr-22-25 Initiated Cantor Fitzgerald Overweight
Dec-10-24 Resumed BofA Securities Buy
Nov-15-24 Initiated Wolfe Research Outperform
Oct-17-24 Initiated Bernstein Outperform
Sep-13-24 Resumed Citigroup Buy
Aug-12-24 Upgrade Deutsche Bank Hold → Buy
Feb-21-24 Downgrade DZ Bank Buy → Hold
Feb-16-24 Reiterated Morgan Stanley Overweight
Dec-21-23 Downgrade Daiwa Securities Buy → Outperform
Nov-09-23 Initiated Deutsche Bank Hold
Oct-20-23 Resumed UBS Buy
Aug-09-23 Upgrade Jefferies Hold → Buy
Jul-26-23 Reiterated Citigroup Buy
Jul-14-23 Initiated HSBC Securities Buy
May-24-23 Reiterated BofA Securities Buy
May-24-23 Reiterated UBS Buy
Mar-13-23 Upgrade Wells Fargo Equal Weight → Overweight
Mar-06-23 Initiated Jefferies Hold
Feb-15-23 Downgrade Societe Generale Hold → Sell
Nov-18-22 Initiated Credit Suisse Outperform
Sep-22-22 Upgrade UBS Neutral → Buy
May-23-22 Initiated SVB Leerink Outperform
Apr-06-22 Resumed Morgan Stanley Overweight
Mar-10-22 Initiated Daiwa Securities Outperform
Jan-21-22 Upgrade DZ Bank Hold → Buy
Jan-03-22 Reiterated Bernstein Mkt Perform
Dec-17-21 Initiated Goldman Neutral
Dec-16-21 Reiterated BMO Capital Markets Outperform
Dec-16-21 Reiterated BofA Securities Buy
Dec-09-21 Resumed Wells Fargo Equal Weight
Nov-19-21 Initiated BMO Capital Markets Outperform
Oct-11-21 Upgrade Berenberg Hold → Buy
Sep-29-21 Upgrade Citigroup Neutral → Buy
Aug-05-21 Upgrade DZ Bank Hold → Buy
Jul-27-21 Resumed Truist Buy
Jun-24-21 Reiterated Cantor Fitzgerald Overweight
Jan-19-21 Upgrade Mizuho Neutral → Buy
Dec-10-20 Upgrade Wolfe Research Peer Perform → Outperform
Nov-10-20 Resumed Bernstein Mkt Perform
Sep-29-20 Initiated Berenberg Hold
Sep-03-20 Upgrade Morgan Stanley Equal-Weight → Overweight
Jun-16-20 Upgrade Guggenheim Neutral → Buy
Apr-21-20 Downgrade UBS Buy → Neutral
Apr-09-20 Downgrade Morgan Stanley Overweight → Equal-Weight
Feb-06-20 Initiated Mizuho Neutral
Dec-18-19 Upgrade Morgan Stanley Equal-Weight → Overweight
Oct-17-19 Resumed BofA/Merrill Buy
May-28-19 Initiated Goldman Buy
Apr-24-19 Upgrade Edward Jones Hold → Buy
Apr-11-19 Downgrade Guggenheim Buy → Neutral
Mar-12-19 Initiated JP Morgan Overweight
Jan-23-19 Initiated UBS Buy
Nov-26-18 Downgrade Citigroup Buy → Neutral
Oct-31-18 Upgrade Credit Suisse Underperform → Neutral
Oct-09-18 Initiated Guggenheim Buy
Oct-01-18 Reiterated SunTrust Buy
Sep-26-18 Resumed JP Morgan Overweight
View All

Lilly Eli Co Stock (LLY) Latest News

pulisher
Oct 29, 2025

Forex Signals Oct 30: BoJ, ECB Steady, Trump Meets Xi; Apple, Amazon, and Eli Lilly Q3 - FXLeaders

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly partners with Walmart to sell weight-loss drug directly to patients nationwide - Fox Business

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Reports Earnings Thursday as Investors Await Trump Drug Pricing Deal - Barron's

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly Takes Big Step Forward In AI With NVIDIA Partnership - Citeline News & Insights

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly (LLY) Anticipates Strong Q3 Earnings Surge - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Partners With Walmart To Expand Access To Popular Weight-loss Drug - Stocktwits

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly to Invest $1.2 Billion in Puerto Rico Manufacturing Expansion - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly (LLY) Invests $1.2 Billion in Puerto Rico Manufacturing Plant - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly Forms Partnership with NVIDIA to Create AI Supercomputer - Pharmaceutical Executive

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Advances AI And Access: Supercomputer With NVIDIA, Zepbound Via Walmart - Benzinga

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly, Walmart to offer first retail pickup option for discounted vials of weight loss drug Zepbound - CNBC

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Pours $1.2 Billion Into Puerto Rico Expansion - Finimize

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly, Walmart launch retail pick-up option for weight loss drug Zepbound - Fierce Healthcare

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly’s New Study on Baricitinib: A Potential Game-Changer for Type 1 Diabetes - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

NVIDIA hits $5T valuation, teams up with Lilly to build AI supercomputer - Mobi Health News

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly plans $1.2B expansion in Puerto Rico, adding 100 manufacturing jobs - Inside INdiana Business

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Commits Over $1.2 Billion to Expand Puerto Rico Manufacturing Hub - BioSpectrum Asia

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly to invest $1.2 billion in Puerto Rico as part of US manufacturing push - WTVB

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly to invest historic $1.2 Billion in expansion - The Weekly Journal

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly, Walmart Announce Expansion of Direct-to Consumer Access for Tirzepatide - Drug Topics

Oct 29, 2025
pulisher
Oct 29, 2025

Jim Cramer on Eli Lilly Stock “Needs Some Kind of Catalyst to Get Things Going” - Yahoo! Finance UK

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly aligns with Walmart in bid to broaden access to discounted Zepbound - BioPharma Dive

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly, Walmart launch discount retail option for weight-loss drug Zepbound - Reuters

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly, Walmart partner to bring Zepbound to customers with direct-to-consumer pricing - KIRO 7 News Seattle

Oct 29, 2025
pulisher
Oct 29, 2025

Walmart, Eli Lilly partner to expand direct-to-consumer Zepbound pricing - Mass Market Retailers

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly to Invest $1.2 Billion in Puerto Rico Plant Expansion - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly (LLY) Pours $1.2 Billion into Puerto Rico Expansion - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly to invest $1.2B in Puerto Rico plant - breakingthenews.net

Oct 29, 2025
pulisher
Oct 29, 2025

Walmart and Eli Lilly to Offer In-Store Pickup for Zepbound With Direct-to-Consumer Pricing - PYMNTS.com

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly expands Zepbound direct-to-patient access through Walmart partnership - Indianapolis Business Journal

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly Announces Partnership with Walmart Pharmacy Launching First Retail Pick-Up Option Offering Direct-To-Consumer Priced Zepbound - Pharmaceutical Commerce

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly announces over $1.2B investment in Puerto Rico faciliy - TipRanks

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly invests $1.2 billion to expand Puerto Rico manufacturing site - StreetInsider

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly announces more than $1.2 billion investment in Puerto Rico facility to boost oral medicine manufacturing capacity in the United States - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

In Lilly vs Novo obesity drug battle, Trump price talks grab focus - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

What's the Driving Force Behind Eli Lilly's Recent Acquisition Spree? - The Globe and Mail

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly (LLY) and Walmart Partner to Expand Access to Zepbound - GuruFocus

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly, Walmart bring retail pick-up option with DTC pricing for Zepbound (WMT:NYSE) - Seeking Alpha

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly strikes deal with Walmart to distribute cash-pay Zepbound vials - Sherwood News

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly, Walmart launch first retail pick-up option for weight-loss drug - Yahoo! Finance Canada

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly, Walmart Launch Discount Retail Option for Weight-Loss Drug Zepbound - US News Money

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly Taps Nvidia to Build Pharma’s Most Powerful AI Supercomputer for Drug Discovery - WinBuzzer

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly acquires Adverum to advance one-time gene therapy for vision loss - BioXconomy

Oct 29, 2025
pulisher
Oct 29, 2025

Why Eli Lilly and Company stock is a strong buy callJuly 2025 Spike Watch & Accurate Trade Setup Notifications - Fundação Cultural do Pará

Oct 29, 2025
pulisher
Oct 29, 2025

Top News Today: Lilly-NVIDIA AI Drug Discovery Deal, Sequoia’s $950M Fund Launch - Analytics Insight

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly and Nvidia team up to build an AI supercomputer dedicated to drug discovery - MarketScreener

Oct 29, 2025
pulisher
Oct 29, 2025

Eli Lilly partners with Nvidia to build AI supercomputer for drug discovery | Mint - Mint

Oct 29, 2025
pulisher
Oct 29, 2025

Opportunities Amid Stock Price Correction? Decoding Eli Lilly’s Moat and Growth Potential - NAI500

Oct 29, 2025
pulisher
Oct 29, 2025

Lilly partners with Nvidia on AI supercomputer to speed up drug development - The Hindu

Oct 29, 2025
pulisher
Oct 28, 2025

Eli Lilly (LLY) To Report Earnings Tomorrow: Here Is What To Expect - Yahoo Finance

Oct 28, 2025
pulisher
Oct 28, 2025

Lilly, Nvidia team up to build pharma’s ‘most powerful’ supercomputer - Indianapolis Business Journal

Oct 28, 2025

Lilly Eli Co Stock (LLY) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
drug_manufacturers_general JNJ
$186.60
price down icon 0.18%
$225.14
price down icon 1.05%
drug_manufacturers_general NVS
$121.80
price down icon 1.32%
drug_manufacturers_general MRK
$86.58
price down icon 0.52%
drug_manufacturers_general NVO
$51.37
price down icon 1.31%
Cap:     |  Volume (24h):